Overexpression of the c-erbB-2 oncoprotein: Why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance?

European Journal of Cancer

Volumn 28, Issue 2-3, 1992, Pages 644-648

  Barnes, D M ^a   Smith, P J ^a   Millis, R R ^a   Bartkova, J ^b   Camplejohn, R S ^c   Gullick, W J ^d  

^a GUY S HOSPITAL   (United Kingdom)

^b the Research Institute of Clinical and Experimental Pathology ^*  (Czech Republic)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN;

ARTICLE; BREAST CARCINOMA; CANCER INFILTRATION; CARCINOMA IN SITU; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL NUCLEUS; FEMALE; HUMAN; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS; RECEPTOR, ERBB-2; S PHASE;

EID: 0026508514     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(05)80117-0     Document Type: Conference Paper

References (31)

1. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
2. Studies of the HER-2/neu proto-oncogene in human breast cancer
3. c-erbB-2 oncoprotein expression in primary advanced breast cancer
4. The long term prognostic significance of c-erbB-2 in primary breast cancer
5. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes
6. Breast cancer and a proto-oncogene. c-erbB-2 is a reliable prognostic marker
7. Follow-up study of HER-2/neu amplification in primary breast cancer
8. Lack of evidence for the prognostic significance of c-erbB-2 amplification in human breast cancer
9. Neu-protein overexpression in breast cancer: association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer
10. Immunohistochemical distribution of c-erbB-2 in in situ breast carcinoma—a detailed morphological analysis
11. Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast
12. Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ
13. Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ
14. Expression of the c-erbB-2 protein in normal and transformed cells
15. An immunohistochemical study of the presence of c-erbB-2 protein in Paget's disease of the nipple
16. In vitro labelling of solid tissues with tritiated thymidine for autoradiographic detection of S-phase nuclei
17. Cell kinetics of histological variants of in situ breast carcinoma
18. Measurement of S-phase fractions in lymphoid tissue comparing fresh versus paraffin-embedded tissue and 4'-6'-diamidino-2 phenyl-indoledihydrochloride versus propridium iodide staining
19. DNA index, S-phase fraction, histological grade and prognosis in breast cancer
20. The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer
21. An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma
22. HER-2/neu amplification and comedo type breast carcinoma
23. Increased erbB-2 gene copies and expression in multiple stages of breast cancer
24. Association of the c-erbB-2 expression and S-phase fraction in the prognosis of node negative breast cancer
25. Comparative long-term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy, and morphometric and clinical features in paraffin-embedded invasive breast cancer
26. erbB-2 amplification in breast cancer with a high rate of proliferation
27. In situ distribution of oncogene products and growth factor receptors in breast carcinoma: c-erbB-2 oncoprotein, EGFr, and PDGFr-β-subunit
28. HER-2/neu oncogene expression and proliferation in breast cancers
29. The risk of occult invasive breast cancer after excisional biopsy showing in situ ductal carcinoma of comedo pattern
30. Non-palpable in situ ductal carcinoma of the breast
31. Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence